Curcumin Analogue A501 induces G2/M Arrest and Apoptosis in Non-small Cell Lung Cancer Cells

  • Xia, Yi-Qun (Chemical Biology Research Center, College of Pharmaceutical Sciences, Wenzhou Medical University) ;
  • Wei, Xiao-Yan (Chemical Biology Research Center, College of Pharmaceutical Sciences, Wenzhou Medical University) ;
  • Li, Wu-Lan (Chemical Biology Research Center, College of Pharmaceutical Sciences, Wenzhou Medical University) ;
  • Kanchana, Karvannan (Chemical Biology Research Center, College of Pharmaceutical Sciences, Wenzhou Medical University) ;
  • Xu, Chao-Chao (Chemical Biology Research Center, College of Pharmaceutical Sciences, Wenzhou Medical University) ;
  • Chen, Da-Hui (Chemical Biology Research Center, College of Pharmaceutical Sciences, Wenzhou Medical University) ;
  • Chou, Pei-Hong (Chemical Biology Research Center, College of Pharmaceutical Sciences, Wenzhou Medical University) ;
  • Jin, Rong (Department of Digestive Diseases, The First Affiliated Hospital of Wenzhou Medical University) ;
  • Wu, Jian-Zhang (Chemical Biology Research Center, College of Pharmaceutical Sciences, Wenzhou Medical University) ;
  • Liang, Guang (Chemical Biology Research Center, College of Pharmaceutical Sciences, Wenzhou Medical University)
  • Published : 2014.08.30


Curcumin and its analogues have been reported to exert anti-cancer activity against a variety of tumors. Here, we reported A501, a new curcumin analogue. The effect of A501 on cell viability was detected by MTT assay, the result showed that A501 had a better inhibiting effect on the four non-small cell lung cancer (NSCLC) cells than that of curcumin. Moreover, Colony forming experiment showed A501 significant restrained cell proliferation. Flow cytometry displayed A501 can cause G2/M arrest and induce apoptosis. Western blotting showed that A501 decreased the expression of cyclinB1, cdc-2, bcl-2, while increased the expression of p53, cleaved caspase-3 and bax. In conclusion, curcumin analogues A501 played antitumor activity by inhibiting cell proliferation and inducing apoptosis of NSCLC cells. And it was likely to be a promising starting point for the development of curcumin-based anticancer drugs.


NSCLC;curcumin;antitumor;cycle arrest;apoptosis


  1. Afaq F, Adhami VM, Ahmad N, et al (2002). Botanical antioxidants for chemoprevention of photocarcinogenesis. Front Biosci, 7, 784-92.
  2. Aggarwal BB, Shishodia S (2006). Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol, 71, 1397-421.
  3. Anand P, Kunnumakkara AB, Newman RA, et al (2007). Bioavailability of curcumin: problems and promises. Mol Pharm, 4, 807-18.
  4. Dai XZ, Yin HT, Sun LF, et al (2013). Potential therapeutic efficacy of curcumin in liver cancer. Asian Pac J Cancer Prev, 14, 3855-9.
  5. Dempke WC, Suto T, Reck M (2010). Targeted therapies for non-small cell lung cancer. Lung cancer, 67, 257-74.
  6. Fang X, Fang L, Gou S, et al (2013). Design and synthesis of dimethylaminomethyl-substituted curcumin derivatives/ analogues: Potent antitumor and antioxidant activity, improved stability and aqueous solubility compared with curcumin. Bioorg Med Chem Lett, 23, 1297-301.
  7. Kamat AM, Tharakan ST, Sung B, et al (2009). Curcumin potentiates the antitumor effects of bacillus calmette-guerin against bladder cancer through the downregulation of NFkappaB and upregulation of TRAIL receptors. Cancer Res, 69, 8958-66.
  8. Kunnumakkara AB, Anand P, Aggarwal BB (2008). Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett, 269, 199-225.
  9. Kunnumakkara AB, Guha S, Krishnan S, et al (2007). Curcumin potentiates antitumor activity of gemcitabine in an orthotopic model of pancreatic cancer through suppression of proliferation, angiogenesis, and inhibition of nuclear factorkappaB- regulated gene products. Cancer Res, 67, 3853-61.
  10. Li PM, Li YL, Liu B, et al (2014). Curcumin inhibits MHCC97H liver cancer cells by activating ROS/TLR-4/caspase signaling pathway. Asian Pac J Cancer Prev, 15, 2329-34.
  11. Li Y, Zhang S, Geng JX, Hu XY (2013). Curcumin inhibits human non-small cell lung cancer A549 cell proliferation through regulation of Bcl-2/Bax and cytochrome C. Asian Pac J Cancer Prev, 14, 4599-602.
  12. Liang G, Shao L, Wang Y, et al (2009). Exploration and synthesis of curcumin analogues with improved structural stability both in vitro and in vivo as cytotoxic agents. Bioorg Med Chem, 17, 2623-31.
  13. Lin SS, Huang HP, Yang JS, et al (2008). DNA damage and endoplasmic reticulum stress mediated curcumin-induced cell cycle arrest and apoptosis in human lung carcinoma A-549 cells through the activation caspases cascade-and mitochondrial-dependent pathway. Cancer Lett, 272, 77-90.
  14. Liu Z, Tang L, Zou P, et al (2014). Synthesis and biological evaluation of allylated and prenylated mono-carbonyl analogs of curcumin as anti-inflammatory agents. Eur J Med Chem, 74, 671-82.
  15. Mo N, Li ZQ, Li J, et al (2012). Curcumin inhibits TGF-beta1- induced MMP-9 and invasion through ERK and Smad signaling in breast cancer MDA- MB-231 cells. Asian Pac J Cancer Prev, 13 , 5709-14.
  16. Nagai S, Kurimoto M, Washiyama K, et al (2005). Inhibition of cellular proliferation and induction of apoptosis by curcumin in human malignant astrocytoma cell lines. J Neurooncol, 74, 105-11.
  17. Ohori H, Yamakoshi H, Tomizawa M, et al (2006). Synthesis and biological analysis of new curcumin analogues bearing an enhanced potential for the medicinal treatment of cancer. Mol Cancer Ther, 5, 2563-71.
  18. Pal SK, Figlin RA, Reckamp K (2010). Targeted therapies for non-small cell lung cancer: an evolving landscape. Mol Cancer Ther, 9, 1931-44.
  19. Prakobwong S, Gupta SC, Kim JH, et al (2011). Curcumin suppresses proliferation and induces apoptosis in human biliary cancer cells through modulation of multiple cell signaling pathways. Carcinogenesis, 32, 1372-80.
  20. Selvam C, Jachak SM, Thilagavathi R, et al (2005). Design, synthesis, biological evaluation and molecular docking of curcumin analogues as antioxidant, cyclooxygenase inhibitory and anti-inflammatory agents. Bioorg Med Chem Lett, 15, 1793-7.
  21. Selvendiran K, Tong L, Vishwanath S, et al (2007). EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression. J Biol Chem, 282, 28609-18.
  22. Sharma RA, Steward WP, Gescher AJ (2007). Pharmacokinetics and pharmacodynamics of curcumin. Adv Exp Med Biol, 595, 453-70.
  23. Starakis I, Nikolakopoulos A, Mazokopakis EE (2012). Targeted therapies for advanced non-small cell lung cancer. Comb Chem High T Scr, 15, 641-55.
  24. Strimpakos AS, Sharma RA (2008). Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Sign, 10, 511-45.
  25. Subramaniam D, May R, Sureban SM, et al (2008). Diphenyl difluoroketone: a curcumin derivative with potent in vivo anticancer activity. Cancer Res, 68, 1962-9.
  26. Tong QS, Zheng LD, Lu P, et al (2006). Apoptosis-inducing effects of curcumin derivatives in human bladder cancer cells. Anti-cancer drugs, 17, 279-87.
  27. Valentini A, Conforti F, Crispini A, et al (2009). Synthesis, oxidant properties, and antitumoral effects of a heteroleptic palladium (II) complex of curcumin on human prostate cancer cells. J Med Chem, 52, 484-91.
  28. Wang Y, Xiao J, Zhou H, et al (2011). A novel monocarbonyl analogue of curcumin, (1E, 4E)-1, 5-bis (2, 3-dimethoxyphenyl)penta-1, 4-dien-3-one, induced cancer cell H460 apoptosis via activation of endoplasmic reticulum stress signaling pathway. J Med Chem, 54, 3768-78.
  29. Wu SH, Hang LW, Yang JS, et al (2010). Curcumin induces apoptosis in human non-small cell lung cancer NCI-H460 cells through ER stress and caspase cascade-and mitochondriadependent pathways. Anticancer Res, 30, 2125-33.
  30. Xiao J, Chu Y, Hu K, et al (2010). Synthesis and biological analysis of a new curcumin analogue for enhanced antitumor activity in HepG 2 cells. Oncol Rep, 23, 1435-41.
  31. Zhang X, Zhang HQ, Zhu GH, et al (2012). A novel monocarbonyl analogue of curcumin induces apoptosis in ovarian carcinoma cells via endoplasmic reticulum stress and reactive oxygen species production. Mol Med Rep, 5, 739-44.
  32. Zhao C, Liu Z, Liang G (2013). Promising curcumin-based drug design: mono-carbonyl analogues of curcumin (MACs). Curr Pharm Design, 19, 2114-35.

Cited by

  1. Curcumin and Inflammatory Bowel Disease: Potential and Limits of Innovative Treatments vol.19, pp.12, 2014,
  2. Curcumin derivative HBC induces autophagy through activating AMPK signal in A549 cancer cells vol.11, pp.1, 2015,
  3. Dendrosomal Curcumin Inhibits Metastatic Potential of Human SW480 Colon Cancer Cells through Down-regulation of Claudin1, Zeb1 and Hef1-1 Gene Expression vol.16, pp.6, 2015,
  4. A Subpopulation of the K562 Cells Are Killed by Curcumin Treatment after G2/M Arrest and Mitotic Catastrophe vol.11, pp.11, 2016,
  5. Mannich Curcuminoids as Potent Anticancer Agents vol.350, pp.7, 2017,
  6. Curcumin induced autophagy anticancer effects on human lung adenocarcinoma cell line A549 vol.14, pp.3, 2017,
  7. ZNF326 promotes proliferation of non-small cell lung cancer cells by regulating ERCC1 expression pp.1530-0307, 2018,
  8. Latest in Vitro and in Vivo Assay, Clinical Trials and Patents in Cancer Treatment using Curcumin: A Literature Review vol.70, pp.4, 2018,